Why is Hims & Hers Health stock sliding today?

Hims & Hers Health stock slipped 1.5% in after-hours trading after the company reported Q2 2026 results that delivered a jarring earnings miss despite a robust revenue beat.

Revenue for the quarter reached $753 million, up 38% year over year and well ahead of analyst expectations, but the company posted an EPS loss of -$0.37, missing the consensus estimate of -$0.05 by a wide margin. The shortfall was driven by gross margin contracting by 12 percentage points, a direct consequence of the ongoing transition from compounded to branded GLP-1 weight-loss medications.

On the positive side, management paired the earnings release with a meaningful guidance upgrade. The company raised its full-year 2026 revenue outlook to a range of $3.1 billion to $3.3 billion, above the prior forecast of $2.8 billion to $3.0 billion, and above the analyst consensus of $3.05 billion. Q3 revenue guidance was set at $880 million to $900 million, with adjusted EBITDA of $75 million to $95 million.

Still, a below-market analyst stance tempered enthusiasm: pre-earnings repositioning, a below-market analyst price target, softening GLP-1 billing data, and unresolved regulatory and legal risks had already combined to push the stock modestly lower ahead of the report. Truist Securities reiterated a Hold rating with a $27 price target, and card data indicated that GLP-1 billings on a daily basis declined 1% month-over-month in July following a 32% expansion in June, raising questions about near-term momentum.

The broader macro environment provided little directional support. The S&P 500 finished the regular session down 0.02%, the Dow Jones edged 0.09% lower, and the Nasdaq was essentially flat, up just 0.04% — leaving sector peers without a meaningful tailwind. Adding to the headwinds, multiple law firms have been investigating the company over alleged securities violations, and the Federal Trade Commission filed a lawsuit in late July alleging that Hims & Hers shared sensitive user health data with third-party advertising platforms — a legal overhang that has weighed on sentiment for weeks.

Taken together, the combination of a significant EPS miss, margin compression from the GLP-1 product mix shift, a cautious analyst community, and lingering legal uncertainty outweighed the revenue beat and raised guidance in the immediate after-hours reaction. The options market had been pricing in roughly a 14.5% move in either direction ahead of the report, making the modest 1.5% decline a relatively contained response — suggesting investors are still processing whether the raised full-year outlook can ultimately justify the near-term profitability pressure.